Infliximab in a patient with refractory mucosal aphthosis.
Jacobi
A
A
Debus
D
D
Schuler
G
G
Hertl
M
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D013281:Stomatitis, Aphthous / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab